Neurocrine Biosciences Inc Financials
Neurocrine Biosciences Inc (NBIX) reported $2.9B in revenue for fiscal year 2025, up 21.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue scale is increasingly flowing through to operating profit and free cash flow, while liquidity expands despite continued reinvestment.
By FY2025, revenue had reached$2.86B while operating margin stood at21.6% . Free cash flow margin also reached26.2% , up from20.6% in FY2021, so the earnings expansion is accompanied by improving cash economics rather than accounting profit alone.
The 2025 cash result supports earnings quality: operating cash flow of
The balance sheet combines ample short-term liquidity with a cash-rich posture: cash reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Neurocrine Biosciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Neurocrine Biosciences Inc has an operating margin of 21.6%, meaning the company retains $22 of operating profit per $100 of revenue. This strong profitability earns a score of 82/100, reflecting efficient cost management and pricing power. This is down from 24.2% the prior year.
Neurocrine Biosciences Inc's revenue surged 21.4% year-over-year to $2.9B, reflecting rapid business expansion. This strong growth earns a score of 84/100.
Neurocrine Biosciences Inc has a moderate D/E ratio of 0.42. This balance of debt and equity financing earns a leverage score of 63/100.
With a current ratio of 3.39, Neurocrine Biosciences Inc holds $3.39 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 81/100.
Neurocrine Biosciences Inc converts 26.2% of revenue into free cash flow ($748.7M). This strong cash generation earns a score of 90/100.
Neurocrine Biosciences Inc earns a strong 14.7% return on equity (ROE), meaning it generates $15 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 78/100. This is up from 13.2% the prior year.
Neurocrine Biosciences Inc scores 8.49, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($15.7B) relative to total liabilities ($1.4B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Neurocrine Biosciences Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Neurocrine Biosciences Inc generates $1.64 in operating cash flow ($782.7M OCF vs $478.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Neurocrine Biosciences Inc generated $2.9B in revenue in fiscal year 2025. This represents an increase of 21.4% from the prior year.
Neurocrine Biosciences Inc's EBITDA was $649.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.6% from the prior year.
Neurocrine Biosciences Inc reported $478.6M in net income in fiscal year 2025. This represents an increase of 40.2% from the prior year.
Neurocrine Biosciences Inc earned $4.67 per diluted share (EPS) in fiscal year 2025. This represents an increase of 41.9% from the prior year.
Cash & Balance Sheet
Neurocrine Biosciences Inc generated $748.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 34.4% from the prior year.
Neurocrine Biosciences Inc held $713.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Neurocrine Biosciences Inc's gross margin was 98.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the prior year.
Neurocrine Biosciences Inc's operating margin was 21.6% in fiscal year 2025, reflecting core business profitability. This is down 2.6 percentage points from the prior year.
Neurocrine Biosciences Inc's net profit margin was 16.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2.2 percentage points from the prior year.
Neurocrine Biosciences Inc's ROE was 14.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 1.5 percentage points from the prior year.
Capital Allocation
Neurocrine Biosciences Inc invested $1.0B in research and development in fiscal year 2025. This represents an increase of 38.9% from the prior year.
Neurocrine Biosciences Inc spent $167.7M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 44.1% from the prior year.
Neurocrine Biosciences Inc invested $34.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 11.0% from the prior year.
NBIX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4B | $2.9B+21.4% | $2.4B+24.8% | $1.9B+26.8% | $1.5B+31.3% | $1.1B+8.4% | $1.0B+32.7% | $788.1M+74.7% | $451.2M+179.2% | $161.6M+977.5% | $15.0M-24.1% | $19.8M | $0-100.0% | $2.9M-94.5% | $53.1M-31.4% | $77.4M |
| Cost of Revenue | $68.6M | $52.1M+53.2% | $34.0M-14.4% | $39.7M+71.1% | $23.2M+62.2% | $14.3M+41.6% | $10.1M | N/A | $4.9M+289.9% | $1.3M | $0 | $0 | N/A | N/A | N/A | N/A |
| Gross Profit | $3.3B | $2.8B+21.0% | $2.3B+25.7% | $1.8B+26.1% | $1.5B+30.9% | $1.1B+8.1% | $1.0B | N/A | $446.3M+178.3% | $160.4M+969.1% | $15.0M-24.1% | $19.8M | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.1B | $1.0B+38.9% | $731.1M+29.4% | $565.0M+21.8% | $463.8M+41.4% | $328.1M+19.3% | $275.0M | N/A | $160.5M+31.8% | $121.8M+29.2% | $94.3M+15.7% | $81.5M+75.5% | $46.4M+18.3% | $39.2M+5.6% | $37.2M+20.1% | $31.0M |
| SG&A Expenses | $1.4B | $1.2B+14.8% | $1.0B+13.5% | $887.6M+17.9% | $752.7M+29.0% | $583.3M+34.6% | $433.3M+22.4% | $354.1M+42.3% | $248.9M+46.5% | $169.9M+149.6% | $68.1M+109.6% | $32.5M+80.6% | $18.0M+34.7% | $13.3M-0.7% | $13.4M+7.9% | $12.5M |
| Operating Income | $794.8M | $619.1M+8.5% | $570.5M+127.4% | $250.9M+0.8% | $249.0M+142.9% | $102.5M-37.1% | $163.0M+125.4% | $72.3M+96.5% | $36.8M+128.0% | -$131.4M+10.9% | -$147.4M-56.4% | -$94.2M-46.3% | -$64.4M-29.7% | -$49.7M-3530.8% | $1.4M-95.7% | $33.9M |
| Interest Expense | N/A | N/A | N/A | $4.6M-35.2% | $7.1M-72.5% | $25.8M-21.3% | $32.8M+2.5% | $32.0M+4.9% | $30.5M+56.2% | $19.5M | $0 | $0 | N/A | N/A | N/A | N/A |
| Income Tax | $234.7M | $226.8M+56.7% | $144.7M+75.6% | $82.4M+38.7% | $59.4M+403.4% | $11.8M+103.9% | -$300.6M-3264.2% | $9.5M+1257.1% | $700K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $705.5M | $478.6M+40.2% | $341.3M+36.7% | $249.7M+61.6% | $154.5M+72.4% | $89.6M-78.0% | $407.3M+1000.8% | $37.0M+75.4% | $21.1M+114.8% | -$142.5M-1.0% | -$141.1M-58.7% | -$88.9M-46.9% | -$60.5M-31.4% | -$46.1M-1017.2% | $5.0M-86.6% | $37.6M |
| EPS (Diluted) | — | $4.67+41.9% | $3.29+33.2% | $2.47+58.3% | $1.56+69.6% | $0.92-77.9% | $4.16+966.7% | $0.39+77.3% | $0.22+113.6% | -$1.62+0.6% | -$1.63-55.2% | -$1.05-29.6% | -$0.81-17.4% | -$0.69-962.5% | $0.08-88.1% | $0.67 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NBIX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.6B+24.5% | $3.7B+14.4% | $3.3B+37.3% | $2.4B+14.3% | $2.1B+19.5% | $1.7B+32.8% | $1.3B+31.5% | $993.2M+21.5% | $817.6M+123.9% | $365.1M-23.1% | $474.8M+95.4% | $243.0M+57.1% | $154.7M-21.1% | $196.0M+41.6% | $138.4M |
| Current Assets | $2.5B+46.3% | $1.7B+7.3% | $1.6B+10.6% | $1.5B+49.4% | $972.8M-4.3% | $1.0B+22.3% | $831.0M+12.6% | $737.8M+33.0% | $554.9M+78.8% | $310.4M-19.2% | $384.1M+93.8% | $198.2M+33.5% | $148.5M-21.6% | $189.3M+42.9% | $132.5M |
| Cash & Equivalents | $713.0M+206.0% | $233.0M-7.2% | $251.1M-4.5% | $262.9M-22.9% | $340.8M+82.1% | $187.1M+66.6% | $112.3M-20.8% | $141.7M-44.4% | $254.7M+205.9% | $83.3M+12.2% | $74.2M+139.2% | $31.0M-30.8% | $44.8M-29.7% | $63.8M+27.2% | $50.1M |
| Inventory | $69.0M+20.2% | $57.4M+49.9% | $38.3M+9.1% | $35.1M+15.1% | $30.5M+8.9% | $28.0M+61.8% | $17.3M+59.2% | $10.9M+960.9% | $1.0M | $0 | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $686.8M+43.4% | $479.1M+9.1% | $439.3M+25.5% | $350.0M+88.7% | $185.5M+18.1% | $157.1M+24.1% | $126.6M+120.5% | $57.4M+84.4% | $31.1M | $0 | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $6.1M+7.0% | $5.7M-1.7% | $5.8M+7.4% | $5.4M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.4B+22.1% | $1.1B+10.8% | $1.0B+54.2% | $660.9M-5.4% | $698.5M+14.8% | $608.5M-9.1% | $669.1M+30.6% | $512.4M+15.0% | $445.5M+787.2% | $50.2M-0.2% | $50.3M+46.6% | $34.3M+0.2% | $34.3M-17.6% | $41.6M-46.9% | $78.3M |
| Current Liabilities | $743.4M+46.4% | $507.7M-22.5% | $654.8M+21.8% | $537.7M+118.8% | $245.8M+31.8% | $186.5M-67.0% | $565.3M+540.7% | $88.2M+62.1% | $54.4M+79.0% | $30.4M+18.3% | $25.7M+64.2% | $15.7M+33.9% | $11.7M-25.2% | $15.6M-66.8% | $47.1M |
| Total Equity | $3.3B+25.6% | $2.6B+16.0% | $2.2B+30.7% | $1.7B+24.3% | $1.4B+22.0% | $1.1B+76.8% | $636.9M+32.5% | $480.8M+29.2% | $372.2M+18.2% | $314.9M-25.8% | $424.5M+103.4% | $208.7M+73.3% | $120.4M-22.0% | $154.4M+156.9% | $60.1M |
| Retained Earnings | $447.7M+1433.2% | $29.2M+118.6% | -$157.1M+61.4% | -$406.8M+36.0% | -$635.8M+12.4% | -$725.4M+36.0% | -$1.1B+3.8% | -$1.2B+1.8% | -$1.2B-13.5% | -$1.1B-15.4% | -$915.2M-10.8% | -$826.3M-7.9% | -$765.8M-6.4% | -$719.7M+0.7% | -$724.7M |
Not reported in any period shown, so not listed: Long-Term Debt.
NBIX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $898.1M | $782.7M+31.5% | $595.4M+52.7% | $389.9M+14.9% | $339.4M+32.3% | $256.5M+12.3% | $228.5M+55.4% | $147.0M+45.0% | $101.4M+207.5% | -$94.3M+11.2% | -$106.2M-179.4% | -$38.0M+19.4% | -$47.1M-59.2% | -$29.6M+16.1% | -$35.3M-4956.4% | -$698K |
| Capital Expenditures | $27.7M | $34.0M-11.0% | $38.2M+35.0% | $28.3M+71.5% | $16.5M-29.5% | $23.4M+114.7% | $10.9M-25.9% | $14.7M-40.7% | $24.8M+257.3% | $6.9M+68.9% | $4.1M+112.4% | $1.9M+20.0% | $1.6M+195.8% | $545K-43.9% | $971K+29.5% | $750K |
| Free Cash Flow | $865.6M | $748.7M+34.4% | $557.2M+54.1% | $361.6M+12.0% | $322.9M+38.5% | $233.1M+7.1% | $217.6M+64.5% | $132.3M+72.7% | $76.6M+175.6% | -$101.3M+8.2% | -$110.3M-176.2% | -$39.9M+18.1% | -$48.8M-61.7% | -$30.2M+16.9% | -$36.3M-2404.5% | -$1.4M |
| Investing Cash Flow | -$891.2M | -$264.4M-108.5% | -$126.8M+72.9% | -$467.1M-163.7% | -$177.1M-36.0% | -$130.2M-3275.6% | $4.1M+101.9% | -$211.1M+13.1% | -$242.9M+3.3% | -$251.3M-322.4% | $113.0M | N/A | N/A | $5.3M+115.4% | -$34.8M-884.2% | -$3.5M |
| Financing Cash Flow | $60.2M | -$38.3M+92.1% | -$486.7M-845.3% | $65.3M+127.9% | -$234.3M-955.1% | $27.4M+117.4% | -$157.8M-587.0% | $32.4M+9.8% | $29.5M-94.3% | $516.6M+21517.0% | $2.4M | N/A | N/A | $5.3M-93.7% | $83.7M+29166.4% | $286K |
| Share Buybacks | $66.0M | $167.7M-44.1% | $300.0M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NBIX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.2%-0.4pp | 98.6%+0.7pp | 97.9%-0.5pp | 98.4%-0.3pp | 98.7%-0.3pp | 99.0% | N/A | 98.9%-0.3pp | 99.2%-0.8pp | 100.0%0.0pp | 100.0% | N/A | N/A | N/A | N/A |
| Operating Margin | 21.6%-2.6pp | 24.2%+10.9pp | 13.3%-3.4pp | 16.7%+7.7pp | 9.0%-6.5pp | 15.6%+6.4pp | 9.2%+1.0pp | 8.2%+89.4pp | -81.3% | -982.5% | -476.5% | N/A | -1701.9% | 2.7%-41.1pp | 43.8% |
| Net Margin | 16.7%+2.2pp | 14.5%+1.3pp | 13.2%+2.8pp | 10.4%+2.5pp | 7.9%-31.0pp | 38.9%+34.3pp | 4.7%0.0pp | 4.7%+92.9pp | -88.2% | -940.6% | -449.8% | N/A | -1579.0% | 9.5%-39.1pp | 48.5% |
| Return on Equity | 14.7%+1.5pp | 13.2%+2.0pp | 11.2%+2.1pp | 9.0%+2.5pp | 6.5%-29.7pp | 36.2%+30.4pp | 5.8%+1.4pp | 4.4%+42.7pp | -38.3%+6.5pp | -44.8%-23.9pp | -20.9%+8.1pp | -29.0%+9.3pp | -38.3%-41.5pp | 3.3%-59.3pp | 62.5% |
| Return on Assets | 10.3%+1.1pp | 9.2%+1.5pp | 7.7%+1.2pp | 6.5%+2.2pp | 4.3%-19.2pp | 23.5%+20.7pp | 2.8%+0.7pp | 2.1%+19.6pp | -17.4%+21.2pp | -38.6%-19.9pp | -18.7%+6.2pp | -24.9%+4.9pp | -29.8%-32.4pp | 2.6%-24.6pp | 27.2% |
| Current Ratio | 3.390.0x | 3.40+0.9x | 2.45-0.2x | 2.70-1.3x | 3.96-1.5x | 5.45+4.0x | 1.47-6.9x | 8.36-1.8x | 10.200.0x | 10.21-4.7x | 14.94+2.3x | 12.650.0x | 12.69+0.6x | 12.10+9.3x | 2.81 |
| Debt-to-Equity | 0.420.0x | 0.440.0x | 0.46+0.1x | 0.39-0.1x | 0.510.0x | 0.54-0.5x | 1.050.0x | 1.07-0.1x | 1.20+1.0x | 0.160.0x | 0.120.0x | 0.16-0.1x | 0.280.0x | 0.27-1.0x | 1.30 |
| FCF Margin | 26.2%+2.5pp | 23.7%+4.5pp | 19.2%-2.5pp | 21.7%+1.1pp | 20.6%-0.3pp | 20.8%+4.0pp | 16.8%-0.2pp | 17.0%+79.6pp | -62.7% | -735.3% | -202.0% | N/A | -1033.0% | -68.2%-66.4pp | -1.9% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Neurocrine Biosciences Inc Ranks
Frequently Asked Questions
What is Neurocrine Biosciences Inc's annual revenue?
Neurocrine Biosciences Inc (NBIX) reported $2.9B in total revenue for fiscal year 2025. This represents a 21.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Neurocrine Biosciences Inc's revenue growing?
Neurocrine Biosciences Inc (NBIX) revenue grew by 21.4% year-over-year, from $2.4B to $2.9B in fiscal year 2025.
Is Neurocrine Biosciences Inc profitable?
Yes, Neurocrine Biosciences Inc (NBIX) reported a net income of $478.6M in fiscal year 2025, with a net profit margin of 16.7%.
What is Neurocrine Biosciences Inc's EBITDA?
Neurocrine Biosciences Inc (NBIX) had EBITDA of $649.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Neurocrine Biosciences Inc's gross margin?
Neurocrine Biosciences Inc (NBIX) had a gross margin of 98.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Neurocrine Biosciences Inc's operating margin?
Neurocrine Biosciences Inc (NBIX) had an operating margin of 21.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Neurocrine Biosciences Inc's net profit margin?
Neurocrine Biosciences Inc (NBIX) had a net profit margin of 16.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Neurocrine Biosciences Inc's return on equity (ROE)?
Neurocrine Biosciences Inc (NBIX) has a return on equity of 14.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Neurocrine Biosciences Inc's free cash flow?
Neurocrine Biosciences Inc (NBIX) generated $748.7M in free cash flow during fiscal year 2025. This represents a 34.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Neurocrine Biosciences Inc's operating cash flow?
Neurocrine Biosciences Inc (NBIX) generated $782.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Neurocrine Biosciences Inc's total assets?
Neurocrine Biosciences Inc (NBIX) had $4.6B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Neurocrine Biosciences Inc's capital expenditures?
Neurocrine Biosciences Inc (NBIX) invested $34.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Neurocrine Biosciences Inc spend on research and development?
Neurocrine Biosciences Inc (NBIX) invested $1.0B in research and development during fiscal year 2025.
What is Neurocrine Biosciences Inc's current ratio?
Neurocrine Biosciences Inc (NBIX) had a current ratio of 3.39 as of fiscal year 2025, which is generally considered healthy.
What is Neurocrine Biosciences Inc's debt-to-equity ratio?
Neurocrine Biosciences Inc (NBIX) had a debt-to-equity ratio of 0.42 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Neurocrine Biosciences Inc's return on assets (ROA)?
Neurocrine Biosciences Inc (NBIX) had a return on assets of 10.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Neurocrine Biosciences Inc's Altman Z-Score?
Neurocrine Biosciences Inc (NBIX) has an Altman Z-Score of 8.49, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Neurocrine Biosciences Inc's Piotroski F-Score?
Neurocrine Biosciences Inc (NBIX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Neurocrine Biosciences Inc's earnings high quality?
Neurocrine Biosciences Inc (NBIX) has an earnings quality ratio of 1.64x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Neurocrine Biosciences Inc?
Neurocrine Biosciences Inc (NBIX) scores 80 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.